secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-005160
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta reports preliminary Q4 2024 net product revenue $638.2M, FY2024 $1.79B, beating guidance by $100M+
--------------------------------------------------------------------------------

- Preliminary total net product revenue Q4 2024 $638.2M, FY2024 $1.79B, exceeding full-year guidance by over $100M.
- ELEVIDYS net product revenue Q4 2024 $384.2M (up 112% sequential), FY2024 $820.8M.
- RNA-based PMO net product revenue Q4 2024 $254.0M, FY2024 $967.2M, grew YoY.
- Cash, cash equivalents, and investments ~$1.5B as of Dec 31, 2024.
- Reiterated 2025 full-year net product revenue guidance of $2.9-3.1B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312525005160/0001193125-25-005160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312525005160/d900352d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-005160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer